Evidence map›Paper›PMID 37441352›Full record

ArticleJAC-antimicrobial resistance2023

Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related

Marguerite L Monogue, James M Sanders, Christine A Pybus, Jiwoong Kim, Xiaowei Zhan, Andrew E Clark, David E Greenberg

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Microbiology spectrum · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Marguerite L MonogueDepartment of Pharmacy, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID https://orcid.org/0000-0001-8251-458X
James M SandersDepartment of Pharmacy, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Christine A PybusDepartment of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Jiwoong KimDepartment of Population and Data Sciences, Quantitative Biomedical Research Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Xiaowei ZhanDepartment of Population and Data Sciences, Quantitative Biomedical Research Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID https://orcid.org/0000-0002-6249-7193
Andrew E ClarkDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
David E GreenbergDepartment of Internal Medicine, Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
The University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Cystic fibrosis (CF) patients are often colonized with Methods: This was a single-centre, non-controlled study. Two hundred and forty-six Results: Sixteen of 26 patient specimens (62%) contained PHR Conclusions: Ceftolozane/tazobactam PHR exists among

Identifiers

PMID37441352
PMCPMC10333726
OpenAlexW4384023117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.